Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer

Inclusion Criteria: * Pathologically confirmed invasive ductal carcinoma or invasive lobular carcinoma of the breast, T2-T4 / T4a-c / N0-2 / M0, with positive estrogen and/or progesterone receptors. Patients with inflammatory breast cancer will not be included (Stage IIIb). Patients previously treated patients with no measurable disease or patients with metastatic disease will be excluded. * Written informed consent prior to study specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice (see Appendix B - consent form). * Females 60 years of age (postmenopausal). * Be ambulatory (outpatient) and have an ECOG PS \<2 (Appendix F). * Patients must have measurable disease by mammogram and/or breast ultrasound. The target lesion must not have been previously irradiated. * No prior chemotherapy. * Patients must have adequate organ and marrow function as defined as follows: absolute neutrophil count \> 1,500/mm3, hemoglobin \> 8.0 g/dl, platelets \> 75,000/mm3, total bilirubin \< 2 mg/dl, serum creatinine \< 2 mg/dl, Transaminases (AST, ALT) may be up to 2.0 x institutional upper limit of normal. In addition \< 1 gr of protein in 24 hr urine collection and urine protein/creatinine ratio \< 1.0. * No life threatening parenchymal disease or rapidly progressing disease warranting cytotoxic chemotherapy. * Hypertension must be controlled (\<150/100 mmHg). * Ejection Fraction \> 50%. * No history of thrombosis during the previous year. Exclusion Criteria: * Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than this sponsor-investigator Bevacizumab cancer study. * Uncontrolled high blood pressure (150/100 mmHg) * Unstable angina * New York Heart Association (NYHA) Grade II or greater congestive heart failure see Appendix G) * History of myocardial infarction within 6 months * History of stroke within 6 months * Clinically significant peripheral vascular disease * History of a bleeding disorder * Presence of central nervous system or brain metastases * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study * Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to Day 0 * Pregnant (positive pregnancy test) or lactating * Urine protein: creatinine ratio 1.0 at screening. Patients demonstrating \> 1 gr of protein in 24 hr urine collection within 4 weeks prior to study entry will not participate in the trial. * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0 * Serious, non-healing wound, ulcer, or bone fracture * Unwilling or unable to comply with the protocol for the duration of the study. * Psychiatric illness/social situations that would limit compliance with study requirements. * History of another malignancy within the last five years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix. * Patients with metastatic disease.